title: The Interaction of Nepafenac and Prostaglandin Analogs in Primary Open-angle Glaucoma Patients.
abstract: OBJECTIVE
  To investigate the effect of nepafenac on intraocular pressure (IOP) in primary open-angle glaucoma (POAG) patients treated with prostaglandin (PG) analogs.
  
  
  METHODS
  This prospective clinical study included 35 patients who had been receiving latanoprost (n=12), travoprost (n=12), or bimatoprost (n=11) for POAG. Nepafenac 0.1% and placebo drops were administered to the right and left eyes of patients, respectively, 3 times a day for 7 days. IOP measurements were taken at 9:00 AM, 12:00 PM, and 4:00 PM at baseline and all consecutive visits. The visits were scheduled on days 1 and 7 during treatment and 1 and 7 days after discontinuation of the treatment.
  
  
  RESULTS
  The mean age of the patients was 60.28±7.51 years (range, 48 to 75 y). The baseline IOP was similar in the nepafenac and placebo groups (15.33±1.45 vs. 15.41±1.41, respectively, P>0.05). The decrease in the mean IOP was significant in the nepafenac group compared with the placebo group throughout the treatment period (P<0.001). After the discontinuation of nepafenac treatment, the mean IOP became similar with the placebo group from the first day (P>0.05). The change in mean IOP was not significant between the PG subgroups during treatment and discontinuation periods (P=0.712).
  
  
  CONCLUSIONS
  Nepafenac potentiates the IOP-lowering effects of 3 different PG analogs in POAG patients.
authors.affiliation: *Department of Ophthalmology, Muğla Sitki Koçman University Faculty of Medicine, Muğla †Department of Biostatistics, Faculty of Medicine, Ankara University, Ankara, Turkey.
authors.forename: Pelin
authors.initials: P
authors.lastname: Özyol
authors.forename: Erhan
authors.initials: E
authors.lastname: Özyol
authors.forename: Beyza Doğanay
authors.initials: BD
authors.lastname: Erdoğan
mesh_terms: D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D044482:Benzeneacetamides / Q000627:therapeutic use*; D000069580:Bimatoprost / Q000627:therapeutic use; D004347:Drug Interactions; D004357:Drug Synergism; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D010648:Phenylacetates / Q000627:therapeutic use*; D011446:Prospective Studies; D011461:Prostaglandins F, Synthetic / Q000627:therapeutic use; D011465:Prostaglandins, Synthetic / Q000627:therapeutic use*; D014065:Tonometry, Ocular; D000069557:Travoprost / Q000627:therapeutic use
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000959:Antihypertensive Agents; D044482:Benzeneacetamides; D009883:Ophthalmic Solutions; D010648:Phenylacetates; D011461:Prostaglandins F, Synthetic; D011465:Prostaglandins, Synthetic; C414203:nepafenac; D000077338:Latanoprost; D000069580:Bimatoprost; D000069557:Travoprost